2023年7月19日

南旧金山,加利福尼亚,美国旧金山,7月19日,2023(全球通讯社)——生物科学文化是兴奋地欢迎艾丽亚娜一直Clark博士,执行副总裁兼首席技术官Intellia疗法,Inc .公司的顾问委员会。一群经验丰富的行业领袖为文化的领导提供了见解和建议公司建立新的伙伴关系,在生物技术和生物制药追求新的增长机会。“我们激动,艾丽亚娜一直借她的经验帮助文化驱动创新,可以克服持久瓶颈在上游生物工艺开发中,“将帕特里克说,首席执行官生物科学文化。“我们相信,先进的技术,例如云软件和数据驱动建模将加速开发新治疗的病人,尤其是在令人印象深刻的新基因和细胞疗法的管道出现。“克拉克艾丽亚娜一直带来超过35年的领导经验的过程,分析和技术开发、CMC的策略,管理和操作,内部和外部的制造、生物制药行业和供应链。“我期待与同事咨询委员会合作,帮助培养生物科学实施亟需的上游生物工艺的创新发展,”克拉克艾丽亚娜一直说,博士,执行副总裁兼首席技术官Intellia疗法,Inc .”生产过程,可以更快和更可靠的扩展将大有帮助创新者公司减少投放市场的时间的新疗法,提高成本效益。”克拉克更多关于艾丽亚娜一直在Intellia她目前的角色之前,克拉克艾丽亚娜一直是公司的高级副总裁,技术操作和质量。她加入了Intellia之前,艾丽亚娜一直举行产品和投资组合管理中的领导角色,制造、制造科学、过程开发和CMC-Regulatory,分别为和赛诺菲安万特/ Genzyme,。加入行业之前,她是塔夫茨大学教授在化学和生物工程部门。举行艾丽亚娜一直在特拉华大学生化工程博士后角色和伍斯特理工学院。她有一个博士和一个化学工程工程学士学位从大学Nacional del沿海地区在圣达菲,阿根廷,毕业于大波士顿麻省理工学院斯隆管理学院执行程序。 About Culture Biosciences’ propriety upstream bioprocess development platform Customers design and monitor their experiments, collaborate on projects, and access and analyze data on a fully integrated platform that offers a wide and flexible range of capacity: 250mL bioreactors and 5L bioreactors, each with single-use vessels for mammalian cell lines or microbial fermentation. The 250mL reactors are mounted in mobile cart modules of four units. Customers can use up to 300 250mL reactors and either complement in-house experiments or outsource them completely. Dedicated and proprietary, cloud-based software to design and monitor experiments remotely, and to integrate and analyze data in one place. Remote, hybrid or multi-location teams can collaborate virtually on this platform. A suite of proprietary tools for process design and data analysis. These tools include a dynamic data analysis suite that enables rapid analysis and understanding of process and offline analytical data. More than 70 client companies have trusted Culture Biosciences’ platform with their upstream bioprocess development in the 5 years since beginning operations in 2018. Customers include large, top-10 biopharma companies, leading CDMOs, and emerging and growing biotech clients. About Culture Biosciences Culture Biosciences is dedicated to innovation in upstream bioprocess development. Culture’s goal is to build new tools and services that improve the performance, time-to-develop, and cost-efficiency of therapeutic manufacturing processes. The company’s proprietary, fully integrated platform combines bioreactors, cloud-based software, and services to offer client companies around the world access to predictable, and scalable bioprocess development. Culture Biosciences was founded in 2016 and is based in South San Francisco, CA. www.culturebiosciences.com